<DOC>
	<DOC>NCT00358644</DOC>
	<brief_summary>The purpose of this study is to estimate the rate of complete remission, as well as overall survival, in older patients with Acute Myeloid Leukemia (AML).</brief_summary>
	<brief_title>Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1. A diagnosis of AML or transformed from myelodysplastic syndrome (MDS) within 2 weeks of study enrollment. 2. Ineligible to receive intensive chemotherapy for their disease. 3. Have not received any chemotherapy within 4 weeks of study enrollment and must have recovered from any treatmentrelated toxicities. 1. Received previous treatment for AML. 2. Previously received Vidaza. 3. Received any other investigational agents within 30 days of first dose of study drug. 4. Uncontrolled intercurrent illness. 5. Had radiotherapy within 14 days prior to study enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
	<keyword>MGI PHARMA, INC.</keyword>
</DOC>